Viridian Therapeutics, Inc./DE Research and Development Expense
Viridian Therapeutics, Inc./DE (VRDN) reported Research and Development Expense of $3.11 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-11-12
- Viridian Therapeutics, Inc./DE research and development expense for the quarter ending 2020-09-30 was $3.11M, a 65.54% decline year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense for the quarter ending 2020-06-30 was $3.84M, a 55.39% decline year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense for the quarter ending 2020-03-31 was $6.10M, a 30.26% decline year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense for the quarter ending 2019-12-31 was $8.42M, a 2.22% increase year-over-year.
- Viridian Therapeutics, Inc./DE research and development expense for fiscal 2019 was $34.79M, a 14.37% increase from fiscal 2018.
- Viridian Therapeutics, Inc./DE research and development expense for fiscal 2018 was $30.42M, a 55.03% increase from fiscal 2017.
- Viridian Therapeutics, Inc./DE research and development expense for fiscal 2017 was $19.62M, a 43.32% increase from fiscal 2016.
- Viridian Therapeutics, Inc./DE research and development expense for fiscal 2016 was $13.69M, a 1266.47% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | $3.11M 10-Q · filed 2020-11-12 | $6.95M derived: sum of 2 quarters · filed 2020-11-12 | $13.05M 10-Q · filed 2020-11-12 | $21.47M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2020-06-30 | $3.84M 10-Q · filed 2020-08-05 | $9.94M 10-Q · filed 2020-08-05 | $18.36M derived: sum of 3 quarters · filed 2020-08-05 | $27.38M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2020-03-31 | $6.10M 10-Q · filed 2020-05-08 | $14.52M derived: sum of 2 quarters · filed 2020-05-08 | $23.55M derived: sum of 3 quarters · filed 2020-11-12 | $32.15M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-12-31 | $8.42M 10-K · filed 2020-03-13 | $17.44M derived: sum of 2 quarters · filed 2020-11-12 | $26.04M derived: sum of 3 quarters · filed 2020-11-12 | $34.79M 10-K · filed 2020-03-13 | ||||
| 2019-09-30 | $9.03M 10-Q · filed 2020-11-12 | $17.63M derived: sum of 2 quarters · filed 2020-11-12 | $26.38M 10-Q · filed 2020-11-12 | $34.61M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $8.60M 10-Q · filed 2020-08-05 | $17.35M 10-Q · filed 2020-08-05 | $25.58M derived: sum of 3 quarters · filed 2020-08-05 | $32.98M derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $8.75M 10-Q · filed 2020-05-08 | $16.98M derived: sum of 2 quarters · filed 2020-05-08 | $24.38M derived: sum of 3 quarters · filed 2020-05-08 | $32.76M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | $8.23M 10-K · filed 2020-03-13 | $15.63M derived: sum of 2 quarters · filed 2020-03-13 | $24.01M derived: sum of 3 quarters · filed 2020-03-13 | $30.42M 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | $7.40M 10-K · filed 2020-03-13 | $15.77M derived: sum of 2 quarters · filed 2020-03-13 | $22.19M 10-Q · filed 2019-11-08 | $27.18M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2018-06-30 | $8.38M 10-K · filed 2020-03-13 | $14.79M 10-Q · filed 2019-08-08 | $19.79M derived: sum of 3 quarters · filed 2020-03-13 | $24.80M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2018-03-31 | $6.41M 10-K · filed 2020-03-13 | $11.41M derived: sum of 2 quarters · filed 2020-03-13 | $16.43M derived: sum of 3 quarters · filed 2020-03-13 | $21.92M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2017-12-31 | $5.00M 10-K · filed 2019-03-14 | $10.02M derived: sum of 2 quarters · filed 2019-03-14 | $15.50M derived: sum of 3 quarters · filed 2019-03-14 | $19.62M 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | $5.02M 10-K · filed 2019-03-14 | $10.51M derived: sum of 2 quarters · filed 2019-03-14 | $14.63M 10-Q · filed 2018-11-07 | $18.53M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-06-30 | $5.49M 10-K · filed 2019-03-14 | $9.61M 10-Q · filed 2018-08-08 | $13.51M derived: sum of 3 quarters · filed 2019-03-14 | $16.48M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-03-31 | $4.12M 10-K · filed 2019-03-14 | $8.03M derived: sum of 2 quarters · filed 2019-03-14 | $10.99M derived: sum of 3 quarters · filed 2019-03-14 | $14.35M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2016-12-31 | $3.91M 10-K · filed 2018-03-15 | $6.87M derived: sum of 2 quarters · filed 2018-03-15 | $10.23M derived: sum of 3 quarters · filed 2018-03-15 | $13.69M 10-K · filed 2018-03-15 | $888.00K 10-K · filed 2017-03-24 | |||
| 2016-09-30 | $2.96M 10-K · filed 2018-03-15 | $226.00K 10-Q · filed 2016-10-26 | $6.32M derived: sum of 2 quarters · filed 2018-03-15 | $9.79M 10-Q · filed 2017-11-09 | $867.00K 10-Q · filed 2016-10-26 | $10.24M derived: sum of 4 quarters · filed 2018-03-15 | ||
| 2016-06-30 | $3.35M 10-K · filed 2018-03-15 | $334.00K 10-Q · filed 2016-08-15 | $6.82M 10-Q · filed 2017-08-11 | $641.00K 10-Q · filed 2016-08-15 | $7.28M derived: sum of 3 quarters · filed 2018-03-15 | $7.53M derived: sum of 4 quarters · filed 2018-03-15 | ||
| 2016-03-31 | $3.47M 10-K · filed 2018-03-15 | $307.00K 10-Q · filed 2016-05-16 | $3.92M derived: sum of 2 quarters · filed 2018-03-15 | $4.17M derived: sum of 3 quarters · filed 2018-03-15 | $4.37M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2015-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $709.00K derived: sum of 2 quarters · filed 2017-03-24 | $903.00K derived: sum of 3 quarters · filed 2017-03-24 | $1.00M 10-K · filed 2017-03-24 | ||||
| 2015-09-30 | $253.00K 10-Q · filed 2016-10-26 | $447.00K derived: sum of 2 quarters · filed 2016-10-26 | $546.00K 10-Q · filed 2016-10-26 | $627.00K derived: sum of 4 quarters · filed 2016-10-26 | ||||
| 2015-06-30 | $194.00K 10-Q · filed 2016-08-15 | $293.00K 10-Q · filed 2016-08-15 | $374.00K derived: sum of 3 quarters · filed 2016-08-15 | $479.00K derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | $100.00K 10-Q · filed 2016-05-16 | $180.00K derived: sum of 2 quarters · filed 2016-05-16 | $285.00K derived: sum of 3 quarters · filed 2016-05-16 | $413.00K derived: sum of 4 quarters · filed 2016-05-16 | ||||
| 2014-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | $185.00K derived: sum of 2 quarters · filed 2016-03-21 | $313.00K derived: sum of 3 quarters · filed 2016-03-21 | $347.00K 10-K · filed 2016-03-21 | $293.00K 10-K · filed 2015-03-27 | |||
| 2014-09-30 | $105.00K 10-Q · filed 2015-11-13 | $76.21K 10-Q · filed 2014-11-14 | $233.00K derived: sum of 2 quarters · filed 2015-11-13 | $267.00K 10-Q · filed 2015-11-13 | $148.29K 10-Q · filed 2014-11-14 | $310.81K derived: sum of 4 quarters · filed 2015-11-13 | ||
| 2014-06-30 | $128.00K 10-Q · filed 2015-08-14 | $9.02K 10-Q · filed 2014-08-14 | $162.00K 10-Q · filed 2015-08-14 | $17.73K 10-Q · filed 2014-08-14 | $205.81K derived: sum of 3 quarters · filed 2015-08-14 | $252.41K derived: sum of 4 quarters · filed 2015-08-14 | ||
| 2014-03-31 | $35.00K 10-Q · filed 2015-05-15 | $77.81K derived: sum of 2 quarters · filed 2015-05-15 | $124.41K derived: sum of 3 quarters · filed 2015-05-15 | $147.23K derived: sum of 4 quarters · filed 2015-05-15 | ||||
| 2013-12-31 | $42.81K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $89.41K derived: sum of 2 quarters · filed 2015-03-27 | $112.23K derived: sum of 3 quarters · filed 2015-03-27 | $225.00K 10-K · filed 2015-03-27 | ||||
| 2013-09-30 | $46.60K 10-Q · filed 2014-11-14 | $69.42K derived: sum of 2 quarters · filed 2014-11-14 | $182.19K 10-Q · filed 2014-11-14 | |||||
| 2013-06-30 | $22.82K 10-Q · filed 2014-08-14 | $68.56K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |